Vanguard Group’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-598,694
| Closed | -$353K | – | 4309 |
|
|
2024
Q4 | $353K | Hold |
598,694
| – | – | ﹤0.01% | 4021 |
|
|
2024
Q3 | $472K | Buy |
598,694
+152,121
| +34% | +$152K | ﹤0.01% | 3984 |
|
|
2024
Q2 | $567K | Buy |
446,573
+49,915
| +13% | +$66K | ﹤0.01% | 3959 |
|
|
2024
Q1 | $551K | Buy |
396,658
+41,435
| +12% | +$68.5K | ﹤0.01% | 3989 |
|
|
2023
Q4 | $565K | Buy |
355,223
+73,196
| +26% | +$93.3K | ﹤0.01% | 3995 |
|
|
2023
Q3 | $400K | Buy |
282,027
+21,650
| +8% | +$33.3K | ﹤0.01% | 4115 |
|
|
2023
Q2 | $414K | Buy |
260,377
+6,495
| +3% | +$8.29K | ﹤0.01% | 4171 |
|
|
2023
Q1 | $213K | Hold |
253,882
| – | – | ﹤0.01% | 4312 |
|
|
2022
Q4 | $361K | Buy |
253,882
+117
| +0% | +$193 | ﹤0.01% | 4186 |
|
|
2022
Q3 | $490K | Hold |
253,765
| – | – | ﹤0.01% | 4213 |
|
|
2022
Q2 | $500K | Sell |
253,765
-1,300
| -0.5% | -$3.15K | ﹤0.01% | 4293 |
|
|
2022
Q1 | $808K | Buy |
255,065
+764
| +0.3% | +$2.67K | ﹤0.01% | 4274 |
|
|
2021
Q4 | $948K | Buy |
254,301
+82,620
| +48% | +$468K | ﹤0.01% | 4281 |
|
|
2021
Q3 | $1.16M | Buy |
171,681
+20,141
| +13% | +$158K | ﹤0.01% | 4213 |
|
|
2021
Q2 | $1.55M | Buy |
151,540
+117,895
| +350% | +$987K | ﹤0.01% | 4041 |
|
|
2021
Q1 | $276K | Buy |
+33,645
| New | +$280K | ﹤0.01% | 4222 |
|
Vanguard Group's CYTH Position: Q1 2025 in Review
Vanguard Group sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q1 2025, closing a stake of 598,694 shares — an estimated $353K sold.
Vanguard Group first reported a position in CYTH in Q1 2021 and held it in 16 quarters. The position peaked at $1.55M in Q2 2021. 0 funds tracked by Wall St. Rank hold CYTH as of Q1 2025.
- Vanguard Group reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Vanguard Group sold 598,694 Cyclo Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $353K.
- Vanguard Group first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q1 2021 and held it in 16 quarters.
- Vanguard Group's Cyclo Therapeutics, Inc. Common Stock position peaked at $1.55M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q1 2025.
Based on Vanguard Group's 13F filing for Q1 2025, filed 9 May 2025.